Search Results

Abzena is opening another manufacturing site, its sixth in a global network. This morning, the partner research organization announced it would build a $200 million facility in Sanford, N.C.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01,

Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates, has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.

Abzena announced the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team.

Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule manufacturing

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ and HydraSpace™.

Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer.

Abzena, plc has signed an antibody humanisation agreement with Tmunity Therapeutics

Abzena, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND. This reduces timeline from stable pool to GMP down to 14 months.

Abzena plc has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US).